M 619 Pill - white capsule/oblong, 21mm
Pill with imprint M 619 is White, Capsule/Oblong and has been identified as Levetiracetam 1000 mg. It is supplied by Mylan Pharmaceuticals Inc.
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 1000 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M 619
Levetiracetam
- Imprint
- M 619
- Strength
- 1000 mg
- Color
- White
- Size
- 21.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients
-
silicon dioxide,
croscarmellose sodium,
magnesium stearate,
microcrystalline cellulose,
polydextrose,
sodium lauryl sulfate,
titanium dioxide,
triacetin
Note: Inactive ingredients may vary.
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 00378-5619 | Mylan Pharmaceuticals Inc. |
| 51079-0860 (Discontinued) | UDL Laboratories Inc. |
Related images for "M 619"
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (430)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
- Levetiracetam Tablets
- Levetiracetam Oral Solution
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.